Marketing-authorisation holder · Spain
Qilu Pharma Spain S.L.
79 medicines in 5 countries, as authorisation holder and marketer.
Loading your page…
Loading your page…
Marketing-authorisation holder · Spain
79 medicines in 5 countries, as authorisation holder and marketer.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
1–25 of 79
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| ABIRATERONA QILU 250 MG COMPRIMIDOS EFG250 mg · Comprimido | Abiraterone | Spain | Authorised | 2022 |
| ABIRATERONA QILU 500 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG500 mg · Comprimido recubierto con película | Abiraterone | Spain | Marketed | 2023 |
| ABIRATERONE QILUCompressa rivestita con film | Abiraterone | Italy | Authorised | |
| APREPITANT QILU 125 MG CAPSULAS DURAS/ APREPITANT QILU 80 MG CAPSULAS DURAS EFG80 mg + 125 mg · Cápsula dura | Aprepitant | Spain | Authorised | 2021 |
| APREPITANT QILU 125 MG CAPSULAS DURAS EFG125 mg · Cápsula dura | Aprepitant | Spain | Authorised | 2021 |
| APREPITANT QILU 80 MG CAPSULAS DURAS EFG80 mg · Cápsula dura | Aprepitant | Spain | Authorised | 2021 |
| BORTEZOMIB QILUSoluzione iniettabile | Bortezomib | Italy | Authorised | |
| BORTEZOMIB QILU 2,5 MG/ML SOLUCION INYECTABLE2,5 mg/ml · Solución inyectable | Bortezomib | Spain | Authorised | 2024 |
| Cefazolin Qilu 1 g prašak za otopinu za injekciju/infuzijuPrašak za otopinu za injekciju / infuziju | Cefazolin | Croatia | Marketed | 2023 |
| CEFAZOLINA QILUPolvere per soluzione iniettabile/per infusione | Cefazolin | Italy | Authorised | |
| CEFAZOLINA QILU 1 G POLVO PARA SOLUCION INYECTABLE Y PARA PERFUSION EFG1.048 g · Polvo para solución inyectable y para perfusión | Cefazolin | Spain | Marketed | 2018 |
| CEFAZOLINA QILU 2 G POLVO PARA SOLUCION INYECTABLE Y PARA PERFUSION EFG2.097 g · Polvo para solución inyectable y para perfusión | Cefazolin | Spain | Marketed | 2018 |
| CEFEPIMA QILU 1 G POLVO PARA SOLUCION INYECTABLE Y PARA PERFUSION EFG1.189 g · Polvo para solución inyectable y para perfusión | Cefepima dihidrocloruro | Spain | Marketed | 2019 |
| CEFEPIMA QILU 2 G POLVO PARA SOLUCION INYECTABLE Y PARA PERFUSION EFG2.378 g · Polvo para solución inyectable y para perfusión | Cefepima dihidrocloruro | Spain | Marketed | 2019 |
| CEFEPIME QILUPolvere per soluzione iniettabile/per infusione | Cefepime | Italy | Authorised | |
| CEFTAROLINA FOSAMIL QILUPolvere per concentrato e soluzione per soluzione per infusione | Ceftaroline fosamil | Italy | Authorised | |
| CEFTAROLINA FOSAMILO QILU 600 MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSION EFG600 mg · Polvo para concentrado para solución para perfusión | Ceftaroline fosamil | Spain | Marketed | 2025 |
| CEFTAZIDIMA QILUSoluzione iniettabile | Ceftazidime | Italy | Authorised | |
| CEFTAZIDIMA QILU 1 G POLVO PARA SOLUCION INYECTABLE Y PARA PERFUSION EFG1165 mg · Polvo para solución inyectable y para perfusión | Ceftazidime | Spain | Marketed | 2019 |
| CEFTAZIDIMA QILU 2 G POLVO PARA SOLUCION INYECTABLE Y PARA PERFUSION EFG2330 mg · Polvo para solución inyectable y para perfusión | Ceftazidime | Spain | Marketed | 2019 |
| Ceftriakson Qilu 1 g prašak za otopinu za injekciju/infuzijuPrašak za otopinu za injekciju / infuziju | Ceftriaxone | Croatia | Marketed | 2022 |
| Ceftriakson Qilu 2 g prašak za otopinu za injekciju/infuzijuPrašak za otopinu za injekciju / infuziju | Ceftriaxone | Croatia | Marketed | 2022 |
| CEFTRIAXONA QILU 1 G POLVO PARA SOLUCION INYECTABLE Y PARA PERFUSION EFG1.193 g · Polvo para solución inyectable y para perfusión | Ceftriaxone | Spain | Marketed | 2019 |
| CEFTRIAXONA QILU 2 G POLVO PARA SOLUCION INYECTABLE Y PARA PERFUSION EFG2.386 g · Polvo para solución inyectable y para perfusión | Ceftriaxone | Spain | Marketed | 2019 |
| CEFTRIAXONE QILUPolvere per soluzione iniettabile/per infusione | Ceftriaxone | Italy | Authorised |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Spain | 52 | 50 | 2 | CompaniesAll medicines |
| Italy | 14 | 14 | 0 | CompaniesAll medicines |
| Croatia | 9 | 9 | 0 | CompaniesAll medicines |
| Netherlands | 3 | 3 | 0 | CompaniesAll medicines |
| European Union (EMA) | 1 | 1 | 0 | CompaniesAll medicines |
Also in the registers of France, United Kingdom
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Source: European Medicines Agency (EPAR data).
Licence: EMA reuse policy (source acknowledgement required)
Fuente de la información: AEMPS (CIMA).
Licence: AEMPS open data reuse with attribution
Source: BDPM (ANSM, HAS, UNCAM).
Licence: Licence Ouverte v1.0
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA presentaciones, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
BDPM / ANSM, HAS and UNCAM; original URLs and each update date retained
Licence: BDPM exact Licence Ouverte v1.0 (October 2011)
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; Category 1 list; publication updated 25 August 2026; acquired 2026-10-15T08:18:47.757811+00:00; original workbook cells and factual authorization/holder projections adapted under Open Government Licence v3.0.
Licence: Open Government Licence v3.0; exact Crown copyright 2026 publication grant
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; Category 2 list; publication updated 25 August 2026; acquired 2026-10-15T08:18:48.423930+00:00; original workbook cells and factual authorization/holder projections adapted under Open Government Licence v3.0.
Licence: Open Government Licence v3.0; exact Crown copyright 2026 publication grant
HALMED, Baza lijekova, source export 08.10.2026., acquired 2026-10-08; factual structured adaptation; Otvorena dozvola RH, NN 67/2017.
Licence: Otvorena dozvola RH
Agenzia Italiana del Farmaco (AIFA); https://www.aifa.gov.it/documents/20142/3815901/Classe_H_per_principio_attivo_31-05-2026.csv; HTTP Last-Modified Mon, 28 Sep 2026 08:46:40 GMT; acquired 2026-10-13T17:21:06.034935+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
Agenzia Italiana del Farmaco (AIFA); https://drive.aifa.gov.it/farmaci/confezioni_fornitura.csv; HTTP Last-Modified Mon, 12 Oct 2026 23:02:44 GMT; acquired 2026-10-13T17:21:16.224007+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
College ter Beoordeling van Geneesmiddelen, Geneesmiddeleninformatiebank metadata, source update 07-10-2026; downloaded 08-10-2026; factual adaptation.
Licence: Conditional noncreative administrative factual metadata; no dataset-wide CC0 claim
Report an error or request removalCorrections from the company itself are welcome.
Other companies in the same group.
Ranked by their number of medicines.